IsoRay News
News
0
Ticker
ISR
ISIN
US46489V1044
IsoRay Eulerpool News
IsoRay Stock News
IsoRay is being monitored by journalists and investors worldwide. We gather the latest IsoRay news here.
- March 6·CNBC
- March 4·CNBC
- March 3·CNBC
- March 2·Yahoo
- February 24·CNBC
- February 8·Yahoo
- January 28·CNBC
- January 27·CNBC
- January 26·Yahoo
- January 20·CNBC
- January 13·CNBC
- January 6·CNBC
- November 10·SeekingAlpha
- October 29·Yahoo
- September 23·Benzinga
- May 13·Yahoo
- April 27·Thefly.com
- April 12·GuruFocus
- March 31·Yahoo
- March 31·Thefly.com
IsoRay Stock Press Releases
IsoRay regularly publishes news on the company's website that are relevant for investors.
- January 12•IsoRay
- December 14•IsoRay
- December 14•IsoRay
- November 10•IsoRay
- October 31•IsoRay
- October 18•IsoRay
- September 29•IsoRay
- September 28•IsoRay
- September 21•IsoRay
- June 21•IsoRay
- June 15•IsoRay
- May 10•IsoRay
- April 29•IsoRay
- March 10•IsoRay
- March 2•IsoRay
- February 8•IsoRay
- January 26•IsoRay
- November 10•IsoRay
- October 29•IsoRay
- September 28•IsoRay
- September 21•IsoRay
- September 21•IsoRay
- September 9•IsoRay
- May 13•IsoRay
- April 29•IsoRay
- April 13•IsoRay
- March 31•IsoRay
- March 3•IsoRay
- February 16•IsoRay
- February 9•IsoRay
IsoRay News 2026
This page contains all current news, analysis and press releases for IsoRay stock (ISR, ISIN: US46489V1044). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at IsoRay.
IsoRay Stock
IsoRay The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations.